Chimerix (United States)

Overview

• IndustryPharmaceutical Preparations¹
• HeadquartersDurham¹
• Websitewww.chimerix.com
• Incorporated inDE³
• Business address2505 Meridian Parkway, Suite 100, Durham, Nc 27713³
• Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under “Risk Factors” in Part I, Item 1A of this Annual Report. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should consider carefully the risks and uncertainties described under “Risk Factors” in Part I, Item 1A of this Annual Report as part of your evaluation of an investment in our common stock.⁴ From its latest annual report

Corporate structure

Chimerix (United States) sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Chimerix (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Properties, in its own words

Our corporate headquarters are located at 2505 Meridian Parkway, Suite 100, Durham, North Carolina 27713 in a facility we lease encompassing approximately 21,325 square feet of office space. The leases for this facility expire in July 2026. We separately lease laboratory space in Durham, North Carolina, encompassing a total of approximately 7,925 square feet. The lease for this laboratory space in Durham expires in July 2026.

We believe that our property and equipment are generally well maintained and in good operating condition.

Item 2 of the 10-K filed Mar 21, 2025.⁴

Leadership

Who has led Chimerix (United States), and when. Pick a name to see everywhere that person has worked.

• Chief executive officerMichael T. Andriole Aug 1, 2023 to now¹⁴
• Chief executive officerMichael A. Sherman Apr 9, 2019 to Aug 1, 2023¹⁵
• Chief executive officerM. Michelle Berrey Apr 11, 2014 to Jan 25, 2019¹⁶
• Chief executive officerKenneth I. Moch Apr 10, 2013 to Apr 7, 2014¹⁷
• PresidentMichael T. Andriole Aug 1, 2023 to now¹⁴
• PresidentM. Michelle Berrey Sep 4, 2014 to Jan 25, 2019¹⁸
• PresidentKenneth I. Moch Apr 10, 2013 to Apr 7, 2014¹⁷
• Chief financial officerMichelle Laspaluto Dec 4, 2023 to now¹⁹
• Chief financial officerMichael T. Andriole Jan 26, 2021 to May 19, 2023²⁰
• Chief financial officerTimothy W. Trost Apr 10, 2013 to May 22, 2019²¹
• Chief operating officerThomas J. Riga Nov 16, 2023 to now²²

Timeline

1. Apr 21, 20258-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer⁵¹
2. Mar 21, 20258-K Results of operations⁵²
3. Mar 5, 20258-K Entered a material agreement; Regulation FD disclosure⁵³
4. Mar 5, 20258-K Entered a material agreement⁵⁴
5. Mar 3, 20258-K Other events⁵⁵
6. Dec 30, 20248-K Entered a material agreement; New debt or obligation; Other events⁵⁶
7. Dec 10, 20248-K Regulation FD disclosure; Other events⁵⁷
8. Nov 14, 20248-K Executive or director change⁵⁸
9. Nov 7, 20248-K Results of operations; Regulation FD disclosure⁵⁹
10. Aug 13, 20248-K Results of operations; Regulation FD disclosure⁶⁰
11. Jul 3, 20248-K Listing notice or transfer⁶¹
12. Jun 21, 20248-K Shareholder vote; Other events⁶²
13. Aug 1, 2023New chief executive Michael T. Andriole becomes CEO¹⁴
14. Apr 9, 2019New chief executive Michael A. Sherman becomes CEO¹⁵
15. Apr 11, 2014New chief executive M. Michelle Berrey becomes CEO¹⁶
16. Apr 10, 2013New chief executive Kenneth I. Moch becomes CEO¹⁷
17. 2000Founded Founded¹

Calendar

When it reported results

1. Mar 21, 2025Reported quarterly or annual results⁵²
2. Nov 7, 2024Reported quarterly or annual results⁵⁹
3. Aug 13, 2024Reported quarterly or annual results⁶⁰
4. May 1, 2024Reported quarterly or annual results⁶³
5. Feb 29, 2024Reported quarterly or annual results⁶⁴
6. Nov 2, 2023Reported quarterly or annual results⁶⁵
7. Aug 3, 2023Reported quarterly or annual results⁶⁶
8. May 4, 2023Reported quarterly or annual results⁶⁷

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

235 filings to the SEC since October 2021: 5 annual reports, 10 quarterly reports, 45 major events, 101 insider forms, 19 large holders, 55 other. The latest 20:

1. May 15, 2025SCHEDULE 13G/A EDGAR
2. May 1, 202515-12G EDGAR
3. Apr 22, 2025EFFECT EDGAR
4. Apr 21, 20254 EDGAR
5. Apr 21, 20254 EDGAR
6. Apr 21, 20254 EDGAR
7. Apr 21, 20254 EDGAR
8. Apr 21, 20254 EDGAR
9. Apr 21, 20254 EDGAR
10. Apr 21, 20254 EDGAR
11. Apr 21, 20254 EDGAR
12. Apr 21, 20254 EDGAR
13. Apr 21, 20254 EDGAR
14. Apr 21, 20254 EDGAR
15. Apr 21, 20254 EDGAR
16. Apr 21, 20254 EDGAR
17. Apr 21, 20254 EDGAR
18. Apr 21, 202525-NSE EDGAR
19. Apr 21, 2025S-8 POS EDGAR
20. Apr 21, 2025S-8 POS EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

29 open-market trades by officers, directors and large owners since October 2021: 13 buys and 16 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G/A, 3 filings Sep 29, 2023 to May 15, 2025⁶⁸
• GLAZER CAPITAL, LLCSCHEDULE 13G, 1 filing Apr 17, 2025⁶⁹
• Rubric Capital Management LPSC 13G/A, 4 filings Feb 14, 2022 to Feb 12, 2024⁷⁰
• Point72 Asset Management, L.P.SC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 2023⁷¹
• MONTANOVA CAPITAL, LLCSC 13G/A, 2 filings May 2, 2022 to Feb 13, 2023⁷²
• Opaleye Management Inc.SC 13G/A, 2 filings Feb 1, 2022 to Feb 13, 2023⁷³
• Peter MollSC 13G, 1 filing Jul 5, 2022⁷⁴
• CANTEX PHARMACEUTICALS, INC.SC 13G/A, 1 filing Feb 3, 2022⁷⁵

SEC filer profile

How Chimerix (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARCHIMERIX INC²
• CIK0001117480
• Employer ID (EIN)33-0903395⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31²
• Industry code (SIC)2834 Pharmaceutical Preparations²
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance²
• Business address2505 Meridian Parkway, Suite 100, Durham, NC 27713²
• Phone919.806.1074²
• Shares outstanding93,803,846 as of Apr 11, 2025⁷⁶
• Public float$74.3M as of Jun 28, 2024⁴
• AuditorErnst & Young LLP, Raleigh, North Carolina PCAOB ID 42; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceAug 5, 2002²
• Filings916 in all: 4 (391), 8-K (156), SC 13G/A (43), 3 (42), 10-Q (36), CT ORDER (28), SC 13G (26), 144 (13)²
  All 52 form types

  S-8 (13), S-8 POS (13), 10-K (12), DEFA14A (12), DEF 14A (11), EFFECT (11), CORRESP (10), 424B5 (9), SC TO-T/A (9), 4/A (8), UPLOAD (7), POS AM (5), REGDEX (4), S-3 (4), S-3ASR (4), D (3), S-1/A (3), SC 14D9/A (3), SC14D9C (3), 10-K/A (2), 10-Q/A (2), 3/A (2), 424B3 (2), 424B4 (2), 8-K/A (2), S-1 (2), S-3/A (2), SC TO-C (2), SCHEDULE 13G (2), SCHEDULE 13G/A (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 5 (1), 8-A12B (1), CERTNAS (1), DRS (1), DRSLTR (1), FWP (1), POSASR (1), S-1MEF (1), SC 13D (1), SC 14D9 (1), SC TO-T (1)

• Latest filingsAnnual report (10-K) Mar 21, 2025
  Quarterly report (10-Q) Nov 7, 2024
  Proxy statement (DEF 14A) Apr 26, 2024
  Latest 8-K (8-K) Apr 21, 2025

Securities registered for trading

From the cover page of the 10-K filed Mar 21, 2025 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Chimerix (United States) names in Item 1A of its 10-K filed Mar 21, 2025: 57 risks under these headings, as written.⁴

• Risks Related to the Merger with Jazz Pharmaceuticals plc
• The pending merger with Jazz Pharmaceuticals Public Limited Company (Jazz) is subject to a number of conditions beyond our control. We may not complete the pending merger with Jazz within the time frame we anticipate or at all, which could have an adverse effect on our business, financial results, and our stock price.
• The pendency of the merger with Jazz could adversely affect our business, financial results and/or results of operations and may impair our ability to attract and retain qualified employees or retain or maintain relationships with our customers, suppliers, other business partners or governmental entities.
• While the Merger Agreement is in effect, we are subject to restrictions on our business activities.
• In certain instances, the Merger Agreement requires us to pay a termination fee to Jazz, which could require us to use available cash that would have otherwise been available for general corporate purposes.
• We have incurred, and will continue to incur, direct and indirect costs as a result of the pending merger with Jazz.
• Risks Related to Our Financial Condition and Need For Additional Capital
• We have incurred significant losses in each year since our inception other than 2022. We anticipate that we will continue to incur significant losses for the foreseeable future.
• Our ability to generate future revenues from product sales is uncertain and depends upon our ability to successfully develop, obtain regulatory approval for, and commercialize product candidates, and even if we generate future revenues, they may not be sufficient to lead to profitability.
• If we fail to obtain additional financing, we could be forced to delay, reduce or eliminate our product development programs, seek corporate partners for the development of our product development programs or relinquish or license on unfavorable terms, our rights to technologies or product candidates.
• If we draw down on our credit facility with Silicon Valley Bank, the terms of our loan and security agreement place restrictions on our operating and financial flexibility, and failure to comply with covenants or to satisfy certain conditions may result in acceleration of our repayment obligations and foreclosure on our pledged assets, which could significantly harm our liquidity, financial condition, operating results, business and prospects and cause the price of our securities to decline.
• We routinely evaluate external assets to build our pipeline of product candidates and there can be no assurance that we will be successful in identifying or completing a transaction for a candidate, that any such transaction will result in additional value for our stockholders or that the process will not have an adverse impact on our business.

Links

• Websitewww.chimerix.com¹
• WikidataQ30268888
• SEC EDGARCIK 1117480